Tag:
PF-03187207
Latest Headlines
Latest Headlines
NicOx retrieves failed glaucoma drug from Pfizer
Shares of NicOx have been buoyed by the news that the French developer has reacquired the rights to an experimental glaucoma therapy that has completed-- and failed --two mid-stage trials. Pfizer gave
Pfizer cancels NicOx drug trial in Asia
In a blow to NicOx, Pfizer decided not to launch a Phase III program for PF-03187207 in Asia. A phase II study compared PF-03187207 to Pfizer's bestselling drug Xalatan and enrolled 112 Japanese
